Active Ingredient(s): Insulin Glargine + Lixisenatide
FDA Approved: * November 21, 2016
Pharm Company: * SANOFI AVENTIS US
Category: Diabetes

Lixisenatide (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of type 2 diabetes. Contents 1 Medical use 1.1 Lixisenatide in neurodegenerative diseases 2 Adverse effects 3 Mechanism of action 4 Chemistry 5 History 6 References 7 External links Medical use Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes.[1] In the European Unio... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.